Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia

A Population Pharmacokinetic Exposure-Response Modeling and Simulation Study

Lihong Du, Larissa A. Wenning, Brendan Carvalho, Lelia Duley, Kathleen Brookfield, Han Witjes, Rik de Greef, Pisake Lumbiganon, Vitaya Titapant, Kiattisak Kongwattanakul, Qian Long, Ussanee S. Sangkomkamhang, Ahmet M. Gülmezoglu, Olufemi T. Oladapo

Research output: Contribution to journalArticle

Abstract

Magnesium sulfate is the anticonvulsant of choice for eclampsia prophylaxis and treatment; however, the recommended dosing regimens are costly and cumbersome and can be administered only by skilled health professionals. The objectives of this study were to develop a robust exposure-response model for the relationship between serum magnesium exposure and eclampsia using data from large studies of women with preeclampsia who received magnesium sulfate, and to predict eclampsia probabilities for standard and alternative (shorter treatment duration and/or fewer intramuscular injections) regimens. Exposure-response modeling and simulation were applied to existing data. A total of 10 280 women with preeclampsia who received magnesium sulfate or placebo were evaluated. An existing population pharmacokinetic model was used to estimate individual serum magnesium exposure. Logistic regression was applied to quantify the serum magnesium area under the curve-eclampsia rate relationship. Our exposure-response model-estimated eclampsia rates were comparable to observed rates. Several alternative regimens predicted magnesium peak concentration < 3.5 mmol/L (empiric safety threshold) and eclampsia rate ≤ 0.7% (observed response threshold), including 4 g intravenously plus 10 g intramuscularly followed by either 8 g intramuscularly every 6 hours × 3 doses or 10 g intramuscularly every 8 hours × 2 doses and 10 g intramuscularly every 8 hours × 3 doses. Several alternative magnesium sulfate regimens with comparable model-predicted efficacy and safety were identified that merit evaluation in confirmatory clinical trials.

Original languageEnglish (US)
JournalJournal of Clinical Pharmacology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Magnesium Sulfate
Eclampsia
Pre-Eclampsia
Pharmacokinetics
Magnesium
Population
Serum
Safety
Intramuscular Injections
Anticonvulsants
Area Under Curve
Logistic Models
Placebos
Clinical Trials
Health
Therapeutics

Keywords

  • eclampsia
  • exposure-response
  • magnesium sulfate
  • population modeling
  • preeclampsia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia : A Population Pharmacokinetic Exposure-Response Modeling and Simulation Study. / Du, Lihong; Wenning, Larissa A.; Carvalho, Brendan; Duley, Lelia; Brookfield, Kathleen; Witjes, Han; de Greef, Rik; Lumbiganon, Pisake; Titapant, Vitaya; Kongwattanakul, Kiattisak; Long, Qian; Sangkomkamhang, Ussanee S.; Gülmezoglu, Ahmet M.; Oladapo, Olufemi T.

In: Journal of Clinical Pharmacology, 01.01.2019.

Research output: Contribution to journalArticle

Du, L, Wenning, LA, Carvalho, B, Duley, L, Brookfield, K, Witjes, H, de Greef, R, Lumbiganon, P, Titapant, V, Kongwattanakul, K, Long, Q, Sangkomkamhang, US, Gülmezoglu, AM & Oladapo, OT 2019, 'Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia: A Population Pharmacokinetic Exposure-Response Modeling and Simulation Study', Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.1448
Du, Lihong ; Wenning, Larissa A. ; Carvalho, Brendan ; Duley, Lelia ; Brookfield, Kathleen ; Witjes, Han ; de Greef, Rik ; Lumbiganon, Pisake ; Titapant, Vitaya ; Kongwattanakul, Kiattisak ; Long, Qian ; Sangkomkamhang, Ussanee S. ; Gülmezoglu, Ahmet M. ; Oladapo, Olufemi T. / Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia : A Population Pharmacokinetic Exposure-Response Modeling and Simulation Study. In: Journal of Clinical Pharmacology. 2019.
@article{ecaaefe2e5c44d2cac388bdff3bc1eaf,
title = "Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia: A Population Pharmacokinetic Exposure-Response Modeling and Simulation Study",
abstract = "Magnesium sulfate is the anticonvulsant of choice for eclampsia prophylaxis and treatment; however, the recommended dosing regimens are costly and cumbersome and can be administered only by skilled health professionals. The objectives of this study were to develop a robust exposure-response model for the relationship between serum magnesium exposure and eclampsia using data from large studies of women with preeclampsia who received magnesium sulfate, and to predict eclampsia probabilities for standard and alternative (shorter treatment duration and/or fewer intramuscular injections) regimens. Exposure-response modeling and simulation were applied to existing data. A total of 10 280 women with preeclampsia who received magnesium sulfate or placebo were evaluated. An existing population pharmacokinetic model was used to estimate individual serum magnesium exposure. Logistic regression was applied to quantify the serum magnesium area under the curve-eclampsia rate relationship. Our exposure-response model-estimated eclampsia rates were comparable to observed rates. Several alternative regimens predicted magnesium peak concentration < 3.5 mmol/L (empiric safety threshold) and eclampsia rate ≤ 0.7{\%} (observed response threshold), including 4 g intravenously plus 10 g intramuscularly followed by either 8 g intramuscularly every 6 hours × 3 doses or 10 g intramuscularly every 8 hours × 2 doses and 10 g intramuscularly every 8 hours × 3 doses. Several alternative magnesium sulfate regimens with comparable model-predicted efficacy and safety were identified that merit evaluation in confirmatory clinical trials.",
keywords = "eclampsia, exposure-response, magnesium sulfate, population modeling, preeclampsia",
author = "Lihong Du and Wenning, {Larissa A.} and Brendan Carvalho and Lelia Duley and Kathleen Brookfield and Han Witjes and {de Greef}, Rik and Pisake Lumbiganon and Vitaya Titapant and Kiattisak Kongwattanakul and Qian Long and Sangkomkamhang, {Ussanee S.} and G{\"u}lmezoglu, {Ahmet M.} and Oladapo, {Olufemi T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jcph.1448",
language = "English (US)",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Alternative Magnesium Sulfate Dosing Regimens for Women With Preeclampsia

T2 - A Population Pharmacokinetic Exposure-Response Modeling and Simulation Study

AU - Du, Lihong

AU - Wenning, Larissa A.

AU - Carvalho, Brendan

AU - Duley, Lelia

AU - Brookfield, Kathleen

AU - Witjes, Han

AU - de Greef, Rik

AU - Lumbiganon, Pisake

AU - Titapant, Vitaya

AU - Kongwattanakul, Kiattisak

AU - Long, Qian

AU - Sangkomkamhang, Ussanee S.

AU - Gülmezoglu, Ahmet M.

AU - Oladapo, Olufemi T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Magnesium sulfate is the anticonvulsant of choice for eclampsia prophylaxis and treatment; however, the recommended dosing regimens are costly and cumbersome and can be administered only by skilled health professionals. The objectives of this study were to develop a robust exposure-response model for the relationship between serum magnesium exposure and eclampsia using data from large studies of women with preeclampsia who received magnesium sulfate, and to predict eclampsia probabilities for standard and alternative (shorter treatment duration and/or fewer intramuscular injections) regimens. Exposure-response modeling and simulation were applied to existing data. A total of 10 280 women with preeclampsia who received magnesium sulfate or placebo were evaluated. An existing population pharmacokinetic model was used to estimate individual serum magnesium exposure. Logistic regression was applied to quantify the serum magnesium area under the curve-eclampsia rate relationship. Our exposure-response model-estimated eclampsia rates were comparable to observed rates. Several alternative regimens predicted magnesium peak concentration < 3.5 mmol/L (empiric safety threshold) and eclampsia rate ≤ 0.7% (observed response threshold), including 4 g intravenously plus 10 g intramuscularly followed by either 8 g intramuscularly every 6 hours × 3 doses or 10 g intramuscularly every 8 hours × 2 doses and 10 g intramuscularly every 8 hours × 3 doses. Several alternative magnesium sulfate regimens with comparable model-predicted efficacy and safety were identified that merit evaluation in confirmatory clinical trials.

AB - Magnesium sulfate is the anticonvulsant of choice for eclampsia prophylaxis and treatment; however, the recommended dosing regimens are costly and cumbersome and can be administered only by skilled health professionals. The objectives of this study were to develop a robust exposure-response model for the relationship between serum magnesium exposure and eclampsia using data from large studies of women with preeclampsia who received magnesium sulfate, and to predict eclampsia probabilities for standard and alternative (shorter treatment duration and/or fewer intramuscular injections) regimens. Exposure-response modeling and simulation were applied to existing data. A total of 10 280 women with preeclampsia who received magnesium sulfate or placebo were evaluated. An existing population pharmacokinetic model was used to estimate individual serum magnesium exposure. Logistic regression was applied to quantify the serum magnesium area under the curve-eclampsia rate relationship. Our exposure-response model-estimated eclampsia rates were comparable to observed rates. Several alternative regimens predicted magnesium peak concentration < 3.5 mmol/L (empiric safety threshold) and eclampsia rate ≤ 0.7% (observed response threshold), including 4 g intravenously plus 10 g intramuscularly followed by either 8 g intramuscularly every 6 hours × 3 doses or 10 g intramuscularly every 8 hours × 2 doses and 10 g intramuscularly every 8 hours × 3 doses. Several alternative magnesium sulfate regimens with comparable model-predicted efficacy and safety were identified that merit evaluation in confirmatory clinical trials.

KW - eclampsia

KW - exposure-response

KW - magnesium sulfate

KW - population modeling

KW - preeclampsia

UR - http://www.scopus.com/inward/record.url?scp=85067069116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067069116&partnerID=8YFLogxK

U2 - 10.1002/jcph.1448

DO - 10.1002/jcph.1448

M3 - Article

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -